In summary, KPT‐330 synergizes with ABT‐199 to induce apoptosis in AML cell lines and primary patient samples at clinically relevant concentrations.12, 32, 51, 52 Both Bcl‐2 and XPO1 are up‐regulated in LSCs and their inhibition by ABT‐199 and KPT‐330, respectively, can selectively target LSCs.2, 35 Importantly, we show that the combination cooperatively inhibits AML primary patient sample leukaemic progenitor cells ex vivo, suggesting that the combination of ABT‐199 and KPT‐330 may show activity against LSCs. Here, XPO1 is linked to acute myeloid leukemia.